Journal of Neurochemistry
© International Society for Neurochemistry
Edited By: Jörg Schulz
Impact Factor: 4.281
ISI Journal Citation Reports © Ranking: 2014: 55/252 (Neurosciences); 72/289 (Biochemistry & Molecular Biology)
Online ISSN: 1471-4159
Effective with the 2014 volume, this journal is published in an online-only format.
We will continue to offer online publication and online reproduction of colour figures free of charge. We envision that the transition to online only will allow us to offer our authors an improved peer review and production service but if you do have any questions or concerns please feel free to contact us at firstname.lastname@example.org.
Did you know... Journal of Neurochemistry has no page charges?
Did you know... Journal of Neurochemistry allows Open Access publication?
Did you know... Journal of Neurochemistry makes review articles freely accessible from publication?
Instructions to Authors
During online submission at ScholarOne (http://mc.manuscriptcentral.com/jneurochem), you should have the following information ready:
- Author/co-author affiliations (name, institution & department at which the work was done (currenct addresses may be listed as such, city,valid email address)
- Title, abstract, up to 6 keywords for the manuscript
- Full name and valid email address of preferred /non-preferred referees and editors.
- Cover letter to the Editor
- ORCID ID (see http://orcid.org)
- Details of whether the manuscript is a resubmission (if yes, you will need to provide the previous manuscript ID), if it has color figures, if you are an ISN member, if the first author is below age 35 (for the manuscript to be eligible for the Mark A. Smith Award), info on funding, institutional approval, conflicts of interests
- All manuscript files:
- Main text file including tables, figure and table legends as .doc, .docx or .rtf
- Figures as .tiff, .eps or .pdf (one file per figure) with at least 300 dpi resolution
- Supplementary Files, if any, merged into one single .pdf file wherever possible
- Cover image suggestion, if any (at least 100 mm high/230 mm wide with 300 dpi resolution)
- The length of manuscripts is restricted (see below). The word count [Abstract, Introduction, Methods, Results, Discussion, Acknowledgments, Figure Legends] will be requested.
Full instructions are provided below. For assistance, please contact the Editorial Office.
1. Journal of Neurochemistry focuses on molecular, cellular and biochemical aspects of the nervous system, the pathogenesis of neurological disorders and the development of disease specific biomarkers. It is devoted to the prompt publication of original findings of the highest scientific priority and value that provide novel mechanistic insights, represent a clear advance over previous studies and have the potential to generate exciting future research.Negative data will be considered, if the research is driven by a strong underlying hypothesis. See: http://mc.manuscriptcentral.com/jneurochem. See: http://mc.manuscriptcentral.com/jneurochem.
Journal of Neurochemistry encourages the use of ORCID, a non-profit, community-based effort to uniquely identify authors and link articles and other research activities to specific individuals. Authors have the opportunity to add their ORCID identifier to their user profiles on https://manuscriptcentral.com/jneurochem or upon submission of an article. Once you provide your ORCID identifier, it will be tied to your profile and automatically available for future submissions. Further information can be found on http://orcid.org/
|Original Articles (full papers)||Short Communications||Systematic reviews||Narrative reviews|
|Format/style||Present a definite new major finding of significant impact. Style described in section II. (Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments/ Conflict of interest disclosure, References, Figure legends)||Provide a broad systematic analysis of resesarch in a specific field. Style as for Original Articles||Unsolicited narrative reviews will be considered but subjected to rigorous editorial assessment. For review suggestions it is recommended to send first a synopsis to the Editor for Reviews. Should be authoritative and topical accounts of the subject area.|
|Length restriction||10 printed pages = 7,500 words + ~6-7 half-page figures and/or tables + references (no limit)||4 printed pages = 3,000 words incl. figure legends + max. 4 figures and/or tables (subtract 500 words for each additional figure) + references||See Narrative Reviews||14 printed pages = 14,000 words (4,000-6,000 words for Mini Reviews) incl. references, figure legends, figures and/or tables (each half-page figure corresponds to about 500 words).|
|Supplements||allowed||not allowed||allowed||not allowed|
Submission of a paper to Journal of Neurochemistry will be held to imply that it represents original research not previously published (except as a meeting abstract, or written dissertation, or non peer-reviewed preliminary report - any of which to be explicitly stated and cited), that it is not being considered for publication elsewhere save the above mentioned exceptions, and that, if accepted, it will not be published elsewhere in similar form, in any language, without the consent of the International Society for Neurochemistry.
4.1 Ethical standards
(a) Authors are expected to abide by accepted ethical standards such as the COPE guidelines:
Experiments should be carried out in accordance with the Guidelines laid down by the relevant National Agency. An according statement needs to be included into the methods. Editors reserve the right to reject papers if there is doubt whether appropriate procedures were followed.
(b) The Chief Editors of JNC expect corresponding authors to refer to the ‘ARRIVE’ guidelines for reporting research (www.nc3rs.org.uk/ARRIVE) before submission of a manuscript. While the guidelines refer to animal experiments, most of the elements are common to all forms of research communication and adherence will strengthen the transparency and completeness of reporting.
(c) Journal of Neurochemistry uses iThenticate plagiarism software as part of the editorial process for manuscripts approaching acceptance. The software identifies matching text in different documents, which can highlight possible cases of plagiarism for the editorial office to investigate further. By submitting their manuscript to this journal authors accept that their manuscript may be screened for plagiarism against their own and others’ previously published works.
(d) Digital images in submissions will be scrutinized for any indication of manipulation that violates the following guidelines, such violation resulting in rejection of the manuscript:
- Specific features within an image must not be enhanced, obscured, (re-)moved or introduced. Adjustments of brightness or contrast are only acceptable if they apply to every pixel in the image and as long as they do not misrepresent any information present in the original (including background). Non-linear adjustments, e.g. as changes in the gamma settings, must be stated.
- Data sets that belong together, e.g. control condition and test condition or different parts from the same gel/blot, should be grouped together. Grouping of images from different gels, fields, exposures, experimental series etc. must be made explicit in the figure and its legend.
The corresponding author should submit documentation or explanation of any image enhancement used. The editors reserve the right to request submission of original unprocessed data from authors should questions arise about the appropriateness of any submitted material. Failure of providing it may result in rejection of the manuscript. Any case in which manipulation affects the interpretation of the data will result in revocation of acceptance. Cases of suspected misconduct will be reported to an author’s home institution or funding agency.
 Developed by the Committee on Publication Ethics (COPE) during the 2nd World Conference on Research Integrity in Singapore in 2010 (see http://publicationethics.org/resources/international-standards)
See also: Wager E & Kleinert S (2011) Responsible research publication: international standards for authors. A position statement developed at the 2nd World Conference on Research Integrity, Singapore, July 22-24, 2010. Chapter 50 in: Mayer T & Steneck N (eds) Promoting Research Integrity in a Global Environment. Imperial College Press / World Scientific Publishing, Singapore (pp 309-16). (ISBN 978-981-4340-97-7).
(a) The corresponding author takes responsibility for the integrity of the work as a whole, from inception to published article. It is assumed that all authors have seen and approved the submission.
(b)Authorship on a manuscript submitted to Journal of Neurochemistry should be based on the following criteria defined by the International Committee of Medical Journal Editors:
- substantial contribution to conception and design, data acquisition, analysis or interpretation;
- drafting the article or revising it critically for important intellectual content; and
- final approval of the version to be published.
If not all criteria are met, contributors should be listed with their respective contribution in the Acknowledgments instead.
4.3 Ethical violations: Definitions and sanctions
Any (suspected) ethical violation, error or mistake - as per the definitions below - reported for a manuscript submitted to or published in Journal of Neurochemistry will be investigated by the Editorial Board. Depending on the kind and severity of the reported problem, the following measures may be taken:
Retraction: A publication identified as having such significant concerns that the veracity of the described findings are unsafe or in doubt. A paper would only be retracted after consultation/agreement between the Chief Editor/Publication Committee, the authors and the publisher, and usually following formal investigation by the institution where the work was carried out and/or a national body.
Corrigendum: A significant error discovered after publication, and shown with its correction on a separate sheet. A solution usually initiated by the authors, with the approval of the publication committee and the publishers.
Erratum: Listing of a relatively minor error in a published work by tacit agreement between the authors, the publication committee, and the publishers.
(i) Data fabrication or plagiarism of data from others
For any work submitted to or already accepted in Journal of Neurochemistry for publication, fabricating or plagiarizing data from others will carry a ban on future submissions for up to the maximum of 8 years.
(ii) Duplicate publication and self-plagiarism
In the case of discernible duplicate publication/self-plagiarism the earliest version will stand as the publication of record and the editors of later versions will be responsible for applying sanctions against authors (below). In the case of duplicate submission/self-plagiarism the editors will not proceed with manuscript review, will inform each other, and apply appropriate sanctions:
Duplicate submission will carry a ban on future submissions for up to 2 years. Self-plagiarism of text, undisclosed conflict or ethical issues will carry anything from a reprimand up to a 2 year ban on submission.
For any work already accepted for publication in Journal of Neurochemistry, a ban on future submissions for up to the maximum of 8 years will be imposed.
4.4 Accessibility of data, materials and associated protocols
Nucleic acid and protein sequences, microarray data, ChIP sequences, proteomic data, metabolomic data, and other data obtained using high throughput sequencing techniques, as well as materials and associated protocols are important products of the scientific enterprise. Any material (including transgenic animals and antibodies) that is key to replication of the reported results must be accessible without undue restriction from the date of publication in order to allow others to replicate and build upon the authors’ claims for decades in the future. Any restriction on the access to material or data must be disclosed at the time of submission. Authors must investigate and disclose any restrictions associated with the human or other tissue they are using. Only material without legal, financial or other restrictions should be used. If the use of material mandates consent forms, any limits that result from those forms must be disclosed upon submission.
Readers who encounter refusal by the authors to comply with these policies should contact the Chief Editor. In cases where editors are unable to resolve a complaint, the journal may refer the matter to the authors' funding institution and/or publish a formal statement of correction, attached online to the publication, stating that readers have been unable to obtain necessary materials to replicate the findings.
4.4.1 Dataset Accessibility
Journal of Neurochemistry expects that data supporting the results in the paper are archived in an appropriate public archive, your own institutional or funder repository, or as Supporting Information on the Journal of Neurochemistry website. Examples of suitable databases are:
DNA Data Bank of Japan (http://www.ddbj.nig.ac.jp)
Protein Data Bank Japan (PDBj, http://www.pdbj.org)
Protein Databank (PDB, http://www.rcsb.org/pdb/)
Worldwide Protein Data Bank (wwPDB, http://www.wwpdb.org)
Authors are expected to archive the complete dataset, along with sufficient details so that a third party can interpret them correctly. No data are to be withdrawn following publication. As discussed by Whitlock et al. (2010), this will likely "require a short additional text document, with details specifying the meaning of each column in the data set. The preparation of such shareable data sets will be easiest if these files are prepared as part of the data analysis phase of the preparation of the paper, rather than after acceptance of a manuscript."
Microarray data should be MIAME compliant (see www.mged.org/Workgroups/MIAME/miame.html, FGED (The Functional Genomics Data) Society: MIAME (Minimum Information About a Microarray Experiment).
The public repositories ArrayExpress at the EBI (UK), GEO at NCBI (US) and CIBEX at DDBJ (Japan) are designed to accept, hold and distribute MIAME compliant microarray data.
The utility of archived data is greatly enhanced when the scripts and input files used in the analyses are also made available. Given that scripts may be a mix of proprietary and freely available code, their deposition is not compulsory, but we nonetheless strongly encourage authors to make these scripts available whenever possible.
Authors may elect to have the data publicly available at the time of publication, or, if the technology of the archive allows, may opt to embargo access to the data for a period up to a year after publication. Exceptions may be granted at the discretion of the editor, e.g. for sensitive information that might compromise the anonymity of human subjects.
An entry name or accession number, together with a direct link, should be included in a ‘Data Accessibility’ section at the end of the “Methods” section at initial submission if available. This should list the database and the respective accession numbers for all data from the manuscript that has been made publicly available. An example follows:
-DNA sequences: Genbank accessions F234391-F234402; NCBI SRA: SRX0110215
-Final DNA sequence assembly: uploaded as online supporting information
-Phylogenetic data: TreeBASE Study accession no. S9345
-R scripts: uploaded as online supporting information
-Sample locations, IMa2 input files and microsatellite data: DRYAD entry doi:10.5521/dryad.1311
Please note that reviewers may be asked to comment on the completeness of the Data Accessibility section.
For additional guidelines on data deposition best practice, please visit http://datadryad.org/depositing or http://data-archive.ac.uk/media/2894/managingsharing.pdf.
If you have any questions about the formatting of this section please contact JNC-CE@ukaachen.de
 Whitlock MC, McPeek MA, Rausher MD, Riesberg LR, Moore AJ (2010) Data archiving. American Naturalist, 175, 145-146.
4.4.2 New scientific/technological developments
Publication of descriptions of new recombinant nucleic acid or monoclonal antibody preparations, chemical compounds, but also (human or animal) cell lines or animal strains will be on the understanding that the authors are willing to supply samples of such materials in response to reasonable scientific requests, which can be defined in a Material Transfer Agreement to be signed by all involved parties. Payment to cover costs of distribution can be requested, and reagents may be made available via commercial or non-commercial third party providers. Information provided on compounds essential for the conclusions of the manuscript must be sufficient to allow others to reproduce them, e.g. describing chemical structure, synthesis and characterization.
4.5 Statistical and data reporting guidelines
Journal of Neurochemsitry follows the “Core set of standards for rigorous reporting of study design (Adapted from Landis et al.)” issued by the NIH ((www.nih.gov/about/reporting-preclinical-research.htm).
Journal of Neurochemistry encourages the use of community-based standards (such as nomenclature standards and reporting standards like ARRIVE, see 4.1(b)), where applicable.
Report how often each experiment was performed and whether the results were substantiated by repetition under a range of conditions. Sufficient information about sample collection must be provided to distinguish between independent biological data points and technical replicates.
Statistics need to be fully reported in the paper, including the statistical test used, exact value of N, definition of center, dispersion and precision measures (e.g., mean, median, SD, SEM, confidence intervals).
State whether the samples were randomized and specify method of randomization, at a minimum for all animal experiments.
State whether experimenters were blind to group assignment and outcome assessment, at a minimum for all animal experiments.
(f) Sample-size estimation
State whether an appropriate sample size was computed when the study was being designed and include the statistical method of computation. If no power analysis was used, include how the sample size was determined.
(g) Inclusion and exclusion criteria
Clearly state the criteria that were used for exclusion of any data or subjects. Include any similar experimental results that were omitted from the reporting for any reason, especially if the results do not support the main findings of the study. Describe any outcomes or conditions that were measured or used and are not reported in the results section.
|Requirements for:||Initial submission||Revision|
|Text and figure requirements|| Prepare manuscript either containing all text, tables, figures and legends and supporting information in a single PDF |
in the format listed under "Revisions" (encouraged)
|Suggestion of referees / handling editors||Suggestions of referees are strongly encouraged (please indicate first name, middle initials (!), last name, valid (!) email address and institution). However there must be no conflicts of interest such as ongoing collaborations, recent joint publications etc. Non-preferred referees may be indicated as well. It is also encouraged to suggest preferred handling editors.|
|Footnotes||Footnotes to the text should be used sparingly, should be indicated by superscript numbers, and typed with corresponding numbers on a separate sheet.|
|Figure & Table requirements|| |
|Manuscripts should be 1.5 to double-spaced throughout and with margins at least 2.5 cm wide. Pages should be numbered in succession, the title page being page 1. They should contain the following sections:|
|1) Title page|| |
|2) Title and Abstract|| |
|3) Introduction|| |
|3) Methods|| |
|4) Results|| |
|5) Discussion|| |
|6) Acknowledgements / Conflict of interest disclosure|| |
|7) References FORMATTING EXAMPLES BELOW|| |
|8) Supporting Information|| |
Journal article: Semenova M. M., Maki-Hokkonen A. M., Cao J., Komarovski V., Forsberg K. M., Koistinaho M., Coffey E. T. and Courtney M. J. (2007) Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death. Nat. Neurosci. 10, 436-443.
Book chapter: Feenstra M. G. P. (2000) Dopamine and noradrenaline release in the prefrontal cortex in relation to unconditioned and conditioned stress and reward, in Progress in Brain Research, (Uylings H. B. M., Van Eden C. G., De Bruin J. P. C., Feenstra M. G. P. and Pennartz C. M. A., eds), Vol. 126, pp. 133-163. Elsevier Science B. V., Amsterdam.
Book: Paxinos G. and Watson C. (1982) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.
Book in series: Di Chiara G. and Gessa G. L., eds (1981) Advances in Biochemical Psychopharmacology, Vol. 27: Glutamate as a Neurotransmitter. Raven Press, New York.
Example for optimization of title and abstract:
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper. If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:
CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp
Drug names should be the official or approved names; trade names or common names may be given in brackets where the drug is first mentioned.
The IUB Enzyme Commission (EC) number must be quoted with the full name of the enzyme when it is first mentioned in the text. Subsequently, the accepted trivial name shall be used, e.g. full name: Acetyl-CoA, choline O-acetyltransferase (EC 188.8.131.52), trivial name: choline acetyltransferase not choline acetylase. For this information the author should refer to Enzyme Nomenclature (1992), Academic Press, San Diego and London. (Units of enzyme activity should be defined in terms of the rate of the reaction catalyzed under specified conditions.) The official Système Internationale (SI) unit is the katal, i.e. mol of substrate transformed (or product formed)/s. However, it may be expressed in other terms, provided clear definitions are given, e.g. µmol/s or µmol/min.
Although SI recommends concentrations to be expressed as mol/L rather than M and that % (wt/vol) and % (vol/vol) should be given as g/L and mL/L, respectively, the use of M, % (wt/vol), and % (vol/vol) will be allowed. N is not permitted. Fractional concentrations should be expressed in decimal form.
Centrifugation conditions should be expressed in terms of g and time; not in revolutions per minute.
(a) The use of abbreviations should be restricted to the Système Internationale (SI) units, see Biochem. J. (1978) 169, 1-27, and a minimum of other generally accepted terms [see (b)]. Excessive use of abbreviations in the text is discouraged.
(b) The following abbreviations may be used without definition.
|ADP||CDP, GDP, IDP, UDP, 5(pyro)-diphosphates of adenosine, cytidine, guanosine, inosine, uridine, etc.|
|AMP||-5-phosphates of adenosine, etc.|
|ATP||-5`(pyro)-triphosphates of adenosine, etc.|
|ANOVA||analysis of variance|
|CoA and acyl-CoA||coenzyme A and its acyl derivatives (e.g., acetyl-CoA)|
|cAMP||3,5-cyclic adenosine monophosphate, etc.|
|cpm||counts per minute|
|dpm||dps-disintegrations per minute/second|
|ELISA||enzyme-linked immunosorbent assay|
|FAD, FADH2||flavin-adenine dinucleotide and its reduced form|
|GABA||gamma-aminobutyric acid (not Gaba)|
|GSSG, GSH||glutathione, oxidized and reduced forms|
|HPLC||high performance liquid chromatography|
|NAD+||NADH-oxidized and reduced forms of nicotin-amide-adenine dinucleotide|
|NADP+||NADPH-oxidized and reduced forms of nicotin-amide-adenine dinucleotide phosphate|
|NAD||NADP may be used when the oxidation state need not be indicated|
|NMR||nuclear magnetic resonance|
|PCR||polymerase chain reaction|
|rpm||revolutions per minute|
|SEM||standard error of mean|
(c) Other abbreviations may be used sparingly and defined in a footnote on the title page, as well as at their first mention in text. Recommended forms of abbreviation to be used with definition are as follows:
ACh, acetylcholine; AChE, acetylcholinesterase; AMPA, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate; ChAT, choline acetyltransferase; COMT, catechol-O-methyltransferase; DA, 3,4-dihydroxyphenylethylamine or dopamine; 5-HT, 5-hydroxytryptamine or serotonin; MAO, monoamine oxidase; NA, noradrenaline, norepinephrine; NeuNAc, N-acetylneuraminic acid (not NANA)
Authors should follow the nomenclature recommended by the International Union of Basic and Clinical Pharmacology (IUPHAR) and the IUPAC-IUB Joint Commission on Biochemical Nomenclature. For references to these rules see Biochemical Nomenclature and Related Documents 2nd edit. (1992), available from Portland Press Ltd., 59 Portland Place, London W1N 3AJ, UK or Portland Press Inc., PO Box 2191, Chapel Hill, NC 27515-2191, USA.
Protein sequences, which have been determined by direct sequencing of the protein, must be submitted to SWISS-PROT at the EMBL Outstation - The European Bioinformatics Institute. Please note that we do not provide accession numbers, IN ADVANCE, for protein sequences that are the result of translation of nucleic acid sequences. These translations will automatically be forwarded to us from the EMBL nucleotide database and are assigned SWISS-PROT accession numbers on incorporation into TrEMBL.
Results from characterization experiments should also be submitted to SWISS-PROT at the EBI. This can include such information as function, subcellular location, subunit etc.
Contact information: SWISS-PROT Submissions, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK. Tel: +44 (0)1223 494400; Fax: +44 (0)1223 494472. Email: email@example.com (for sequence admissions) firstname.lastname@example.org (for characterization information) Website: www.ebi.ac.uk
1. OnlineOpen / Open Access
4. Digitisation of JNC
5. Accepted Articles (“Early Online”)
6. Enquiries concerning papers in press
7. Online production tracking
8. NIH-funded authors and Journal of Neurochemistry
Contributors to this journal may choose to make their articles open access and available free for all readers. For options, see: http://olabout.wiley.com/WileyCDA/Section/id-406241.html.
OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms.
Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website at: https://authorservices.wiley.com/bauthor/onlineopen_order.asp
Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.
For authors choosing OnlineOpen
If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
Creative Commons Attribution License OAA
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) or the Austrian Science Fund (FWF) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with your Funder requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.
All information about the proofs will be sent to the author submitting the paper and corrected proofs must be returned promptly. This will allow correction of typesetters and similar errors. Authors will be sent an email alerting them that proofs are available to download from our secure designated author website. Authors who fail to download the proofs will be sent their proofs via email as an Acrobat PDF (portable document format) file. Therefore, the corresponding author should supply their email address when they submit their manuscript. The email server must be able to accept attachments up to 4 MB in size. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the following Web site: http://get.adobe.com/uk/reader/
To assure prompt publication, proofs should be returned not more than 3 working days after receipt. Corrections should be restricted to typesetter errors and completion of in press references.
Substantial alterations to proofs may delay publication and also be charged to authors.
Free access to the final PDF offprint of your paper will be available via author services only. Authors may therefore sign up for author services if they would like to access their article PDF offprint and enjoy the many other benefits this service offers. Paper offprints may be ordered at prices quoted on the order form, which accompanies proofs, provided that the form is returned with the proofs. The cost is more if the order form arrives too late for the main print run. Offprints are normally dispatched within three weeks of publication of the issue in which the paper appears. The publisher may be contacted if offprints do not arrive. Offprints are sent by surface mail.
Wiley-Blackwell and The International Society for Neurochemistry have digitised the entire run of JNC back to volume one, issue one. The back files, which have been defined as all of those issues published before 1997, will be sold to libraries as part of Wiley-Blackwell's Publishing's Legacy Sales Programme and hosted on the Wiley Online Library.
Journal of Neurochemistry offers Accepted Articles. Accepted Articles have been accepted for publication and undergone full peer review but have not been through the copyediting, typesetting, pagination and proofreading process. Accepted Articles are published online a few days after final acceptance, appear in PDF format only, are given a Digital Object Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed. A completed copyright form is required before a manuscript can be processed as an Accepted Article. Graphics are placed at the end of the PDF and may be compressed to reduce download time of the PDF. Once the manuscript has been through the production process (approximately 30 days) the article is removed from the Accepted Articles area and published as normal.
All enquiries concerning the status of manuscripts accepted for publication should be directed to: Production Editors, Journal of Neurochemistry (Email: email@example.com)
This is now available for articles through Wiley-Blackwell's Author Services. Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated emails at key stages of production. The author will receive an email with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete email address is provided when submitting the manuscript. Visit http://authorservices.wiley.com/bauthor/ for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.
The NIH mandates grantees to deposit their peer-reviewed author manuscripts in PubMed Central, to be made publicly available within 12 months of publication. The NIH mandate applies to all articles based on research that has been wholly or partially funded by the NIH and that are accepted for publication on or after April 7, 2008. In order to help authors comply with the NIH mandate, for papers accepted for publication in Journal of Neurochemistry, Wiley-Blackwell will post the accepted manuscript (incorporating all amendments made during peer review, but prior to the publisher's copy-editing and typesetting) of articles by NIH grant-holders to PubMed Central at the point of acceptance by the journal. This version will then be made publicly available in PubMed Central 12 months after publication. Following the deposit Wiley-Blackwell authors will receive further communications from the NIH with respect to the submission. For further information, see here.
If authors wish to make their final published article openly accessible and without a 12 month embargo, they can choose to publish via the OnlineOpen service.
Wellcome and HHMI grantees can find out further information here.
Author Guidelines last updated 11 July 2014